skip to main content

Centrastate Medical Center Offers New, Minimally Invasive Procedure That Provides Relief for Men With Benign Prostatic Hyperplasia (BPH)

By |2022-12-08T12:48:38-05:00August 11th, 2022|

CentraState Medical Center has begun offering patients the latest UroLift® 2 System that uses the Prostatic Urethral Lift procedure for patients with Benign Prostatic Hyperplasia (BPH), a non-cancerous condition that can negatively impact a man’s quality of life.

Surgeon Troy Sukkarieh, MD, recently performed the first Urolift procedure using the new Urolift device in a Monmouth County hospital setting. The procedure is ideal for those with BPH who experience the urgent need to urinate, difficulty starting a urine stream, increased frequency of urination and other symptoms.

“The technology allows us to perform the procedure in just a few minutes, so the total time spent at the hospital is two-four hours rather than days,” says Dr. Sukkarieh. “There is very little recovery time because most men don’t need a catheter, and patients have been very pleased with the results and lack of side effects.”

BPH is a common condition in which the prostate enlarges as men age, affecting nearly 40 million Americans and 500 million men worldwide. Most men living with BPH symptoms take prescription medications after they’re diagnosed, although these may not provide adequate relief and can cause dizziness, fatigue, and sexual dysfunction.

The UroLift® 2 System treatment offers a mechanical method that yields rapid, lasting relief from BPH, which results from an enlarged prostate that narrows or blocks the urethra. During the outpatient procedure, a device is placed through the obstructed urethra to access the prostate, allowing the surgeon to insert tiny implants on either side of the prostate to hold open the obstructed pathway that blocks urine flow.

“Left untreated, those with BPH may be at risk for permanent bladder damage, urinary tract infections or other problems that develop over time” added Dr. Sukkarieh.

The UroLift System is covered nationally by Medicare and by most major private insurance payors.


The UroLift System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100 cc in men 45 years or older (50 years outside U.S.). The UroLift permanent implants, which can be delivered during an outpatient procedure, relieve prostate obstruction without heating, cutting, destruction of, or removing prostate tissue. The UroLift System can be used to treat a broad spectrum of anatomies, including obstructive median lobe.5 It is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction.*6-8 Most common adverse events are temporary and can include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence.9 Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. The prostatic urethral lift procedure (using the UroLift System) is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. More than 350,000 men have been treated with the UroLift System in select markets worldwide.1 Learn more at Rx only.


If you are a member of the media and have an inquiry or would like to schedule an interview with an executive, physician, or other clinician, please contact the Public Relations Department at 732-294-7080 during business hours. If the matter is urgent you may also call or text Lori Palmer, Director of Public Relations & Communications at 609-707-5590 or by emailing

Keep updated with the latest